CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" Association Between Functional Impairment and Medication Burden in Adults with Heart Failure Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure The Hospital Readmissions Reduction Program Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions

Clinical TrialNov. 17, 2019

JOURNAL:Circulation. Article Link

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

MN Kosiborod, PJhund, KF Docherty et al. Keywords: dapagliflozin; HFrEF; quality of life; cardiovascular outcomes

FULL TEXT PDF